Toll样受体9及其配体研究进展  

Recent Advances in Toll-like Receptor 9 and Its Ligands

作　　者：钱旭波 蔡晓红[2] 

机构地区：[1]浙江省义乌东方医院,浙江义乌322000 [2]温州医学院附属育英儿童医院,浙江温州325027

出　　处：《医学综述》2010年第19期2886-2888,共3页Medical Recapitulate

基　　金：浙江省义乌市科研计划项目(08-3-05);温州市科技局项目(Y20080182)

摘　　要：哺乳动物的免疫系统通过模式识别受体来识别病原微生物,Toll样受体(TLR)9是主要的先天性免疫模式识别受体之一。TLR9的天然配体是病毒和细菌基因组中的非甲基化胞嘧啶-磷酸-鸟嘌呤二核苷酸序列(CpG),实验研究中多采用人工合成的具有抗核酶降解作用的类似物——含有CpG基序的寡聚脱氧核苷酸。TLR9被其配体激动后可使机体产生强烈的Th1型优势免疫应答,在变态反应性疾病、感染性疾病和癌症方面的治疗中有广泛的应用前景。The mammalian immune system senses pathogens through pattern recognition receptors.Toll-like receptor 9（TLR9）is one of innate immune pattern recognition receptors,and its natural ligands are unmethylated CpG dinucleotides（CpG-DNA）in the genomes of bacteria and viruses.Investigations of TLR9 stimulation in animal experiments and human trials generally use synthetic CpG ODN that have a nuclease-resistant backbone for improved stability.The activation of TLR9 by its ligands induces a strong T-helper-1 dominant immune response and has a prosperous future in the treatment of allergies,infectious diseases,and cancers.

关 键 词：TOLL样受体9 配体 非甲基化胞嘧啶-磷酸-鸟嘌呤二核苷酸序列 含有CpG基序的寡聚脱氧核苷酸 

分 类 号：R392.9[医药卫生—免疫学]